Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02924766
Recruitment Status : Active, not recruiting
First Posted : October 5, 2016
Last Update Posted : June 21, 2019
Sponsor:
Information provided by (Responsible Party):
Janssen Research & Development, LLC

Brief Summary:
The purpose of this study is to assess the safety and pharmacokinetics of niraparib when administered in combination with an androgen receptor (AR)-targeted therapy (apalutamide or abiraterone acetate plus prednisone) in adult men with metastatic castration resistant prostate cancer (mCRPC) who may or may not have deoxyribonucleic acid (DNA)-repair anomalies.

Condition or disease Intervention/treatment Phase
Prostatic Neoplasms Drug: Niraparib Drug: Apalutamide Drug: Abiraterone Acetate Drug: Prednisone Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 34 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Safety and Pharmacokinetics Study of Niraparib Plus Androgen Receptor-Targeted Therapy (Apalutamide or Abiraterone Acetate Plus Prednisone) in Men With Metastatic Castration-Resistant Prostate Cancer
Actual Study Start Date : October 2016
Estimated Primary Completion Date : June 2019
Estimated Study Completion Date : July 2019


Arm Intervention/treatment
Experimental: Niraparib + Apalutamide/[Abiraterone Acetate + Prednisone]
Participants will receive initial starting dose of Niraparib 200 milligram (mg) once daily in combination either with Apalutamide 240 mg (4*60 mg) once daily or Abiraterone Acetate 1000 mg (4*250 mg) plus 10 mg Prednisone (5 mg twice daily) for 28 days of cycle 1. Once a safe dose of niraparib is selected with each Andrgen Receptor (AR)-targeted therapy [Apalutamide or Abiraterone Acetate plus Prednisone], then an expansion phase (Part 2) will open to further explore safety and assess antitumor activity.
Drug: Niraparib
Participants will start with niraparib 200 mg once daily.
Other Name: JNJ-64091742

Drug: Apalutamide
Participants will receive apalutamide 240 mg (4*60 mg) once daily orally.
Other Name: ARN-509

Drug: Abiraterone Acetate
Participants will receive 1000 mg (4*250mg) once daily.
Other Name: ZYTIGA

Drug: Prednisone
Participants will receive 10 mg (1*5 mg twice daily).




Primary Outcome Measures :
  1. Determine Recommended Phase 2 dose (RP2D) of Niraparib in Combination With 240 milligram (mg) Apalutamide or 1,000 mg Abiraterone Acetate Plus 10 mg Prednisone (5 mg Twice Daily) in Part 1 [ Time Frame: Up to 56 days ]
    RP2D will be defined as the highest dose of study drug at which less than 33 percent (%) of participants experience dose limiting toxicity (DLT).

  2. Number of Participants With Incidence and Severity of Adverse Events (Part 2) [ Time Frame: Up to 30 days after last dose ]
    Number of participants will be assessed to further explore safety and antitumor activity in Part 2 (dose expansion) of study.


Secondary Outcome Measures :
  1. Maximum Observed Plasma Concentration (Cmax) [ Time Frame: 24 hours postdose on Cycle 1 Day 1 up to 10 hours postdose Cycle 3 Day 1 (each cycle 28 days) ]
    Maximum observed plasma concentration (Cmax) will be assessed.

  2. Time to Reach the Maximum Observed Plasma Concentration (Tmax) [ Time Frame: 24 hours postdose on Cycle 1 Day 1 up to 10 hours postdose Cycle 3 Day 1 (each cycle 28 days) ]
    Time to reach the maximum plasma concentration(Tmax) will be assessed.

  3. Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC [0-24]) [ Time Frame: 24 hours postdose on Cycle 1 Day 1 up to 10 hours postdose Cycle 3 Day 1 (each cycle 28 days) ]
    Area under plasma concentration-time curve from time 0 to time 24 hours after dosing will be assessed.

  4. Trough Plasma Concentration (Ctrough) [ Time Frame: Predose (Cycle 1 Days 15 and 22) up to Cycle 3 Day 1 (each cycle 28 days) then Every 3 Cycles after Cycle 3 till End of Treatment (30 days after last dose) ]
    Ctrough is the minimum observed (that is, predose) plasma concentration following multiple dosing will be assessed.

  5. Metabolite to Parent Ratio for Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC [0-24]) [ Time Frame: 24 hours postdose on Cycle 1 Day 1 up to 10 hours postdose Cycle 3 Day 1 (each cycle 28 days) ]
    Metabolite to parent drug ratio for area under the plasma concentration-time curve from time 0 to 24 hours (AUC [0-24]) will be assessed.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed prostate cancer (mixed histology is acceptable, with the exception of the small cell pure phenotype, which is be excluded
  • At least 1 line of prior taxane-based chemotherapy
  • At least 1 line of prior androgen receptor (AR) targeted therapy
  • Progression of metastatic prostate cancer in the setting of castrate levels of testosterone or history of bilateral orchiectomy at study entry
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) of lesser than or equal to [<=]1

Exclusion Criteria:

  • Known brain metastases or history of seizure
  • Prior treatment with a poly (adenosine diphosphate [ADP] ribose) polymerase (PARP) inhibitor
  • Prior platinum-based chemotherapy for the treatment of prostate cancer
  • Known history or current diagnosis of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)
  • Severe or unstable cardiovascular disease or uncontrolled hypertension
  • Left ventricular ejection fraction (LVEF) of lesser than [<] 50 percent (%) as determined by multiple uptake gated acquisition (MUGA) or echocardiography during screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02924766


Locations
Layout table for location information
United States, California
West Hollywood, California, United States
United States, Kentucky
Louisville, Kentucky, United States
United States, Oregon
Portland, Oregon, United States
United States, South Carolina
Myrtle Beach, South Carolina, United States
Canada, British Columbia
Vancouver, British Columbia, Canada
Canada, Quebec
Montreal, Quebec, Canada
Sponsors and Collaborators
Janssen Research & Development, LLC
Investigators
Layout table for investigator information
Study Director: Janssen Research & Development, LLC Clinical Trial Janssen Research & Development, LLC

Layout table for additonal information
Responsible Party: Janssen Research & Development, LLC
ClinicalTrials.gov Identifier: NCT02924766     History of Changes
Other Study ID Numbers: CR108230
2016-002694-35 ( EudraCT Number )
64091742PCR1001 ( Other Identifier: Janssen Research & Development, LLC )
First Posted: October 5, 2016    Key Record Dates
Last Update Posted: June 21, 2019
Last Verified: June 2019

Layout table for additional information
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Prednisone
Abiraterone Acetate
Niraparib
Androgens
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Hormone Antagonists
Cytochrome P-450 Enzyme Inhibitors
Poly(ADP-ribose) Polymerase Inhibitors